Top stories from the Proactive Investors UK newsroom.
ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and secondary endpoints with the data now being collated for independent review.
Avacta (LON:AVCT) is to partner with Swiss group Selexis to develop cell lines for in-human clinical trials. Avacta's first Affimer clinical candidate will be used as the basis of therapies for solid tumours.
Fuel cell specialist Ceres Power (LON:CWR) and Japan's leading industrial boiler manufacturer have launched their first product together. The new fuel cell system is a 4.2kW combined heat and power unit that will provide both clean energy and hot water to commercial buildings.
An update this morning from Shanta Gold (LON:SHG) and Phase 2 drilling at Bauhinia Creek. It’s one of three active sources of ore currently being mined at New Luika.
Dixons Carphone has warned of more pain in the coming year as it restructures its UK mobile arm. Underlying profits tumbled in the year to April to £298mln and will drop to £210mln as mobile will make a big loss.
Household goods retailer Dunelm has upgraded its profit expectations after strong trading. May and June in particular saw very good sales and as a result Dunelm’s profits will be around 22% higher.